| Drug Name |
Thiotepa |
| Drug ID |
BADD_D02203 |
| Description |
N,N'N'-triethylenethiophosphoramide (ThioTEPA) is a cancer chemotherapeutic member of the alkylating agent group, now in use for over 50 years. It is a stable derivative of N,N',N''- triethylenephosphoramide (TEPA). It is mostly used to treat breast cancer, ovarian cancer and bladder cancer. It is also used as conditioning for Bone marrow transplantation. Its main toxicity is myelosuppression. |
| Indications and Usage |
ThioTEPA is used a as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients. Also, when high dose chemotherapy with HPCT support it is appropriate for the treatment of solid tumours in adult and paediatric patients. |
| Marketing Status |
approved; investigational |
| ATC Code |
L01AC01 |
| DrugBank ID |
DB04572
|
| KEGG ID |
D00583
|
| MeSH ID |
D013852
|
| PubChem ID |
5453
|
| TTD Drug ID |
D00YZA
|
| NDC Product Code |
68083-503; 0143-9309; 69539-123; 70225-1104; 65219-029; 69539-124; 58621-004; 70860-220; 72205-046; 43598-650; 70121-1631; 72205-045; 54893-0045; 43598-171; 70121-1630; 54875-0004; 25021-246; 0143-9565; 54879-014; 68083-446; 50683-0465 |
| UNII |
905Z5W3GKH
|
| Synonyms |
Thiotepa | Thio-Tepa | Thio Tepa | Tris(1-aziridinyl)phosphine Sulfide | Thiophosphamide | Triethylenethiophosphoramide | Tespamin | NSC-6396 | NSC 6396 | NSC6396 | Tespa | AI3-24916 | AI3 24916 | AI324916 | Girostan |
